Please Wait.....
Report
Pneumococcal Vaccine Market Report and Forecast 2024-2032
Market Report I 2023-10-01 I 160 Pages I EMR Inc.
Global Pneumococcal Vaccine Market Report and Forecast 2024-2032
Global Pneumococcal Vaccine Market Outlook
The global pneumococcal vaccine market size was valued at USD 8.61 million in 2023, driven by the heightened recognition of the importance of preventive measures against pneumococcal diseases, which can lead to conditions such as pneumonia, meningitis, and sepsis across the globe. The market size is anticipated to grow at a CAGR of 4.9% during the forecast period of 2024-2032 to achieve a value of USD 13.21 million by 2032.
Pneumococcal Vaccine: Introduction
Pneumococcal vaccines are vital tools in the prevention of diseases caused by the Streptococcus pneumoniae bacteria. This bacterium can lead to a range of serious conditions, including pneumonia, meningitis, and bloodstream infections, particularly in young children, the elderly, and individuals with compromised immune systems. The pneumococcal vaccines stimulate the immune system to produce antibodies against specific serotypes or strains of the bacteria, offering protection against subsequent infections.
There are two primary types of pneumococcal vaccines: the pneumococcal conjugate vaccine (PCV) and the pneumococcal polysaccharide vaccine (PPSV). Each targets different serotypes and is recommended based on age and health conditions. The widespread use of these vaccines has significantly reduced the incidence of pneumococcal diseases in many parts of the world, showcasing their importance in public health initiatives.
Key Trends in the Global Pneumococcal Vaccine Market
The global pneumococcal vaccine market is witnessing several dynamic trends that reflect the global commitment to combat pneumococcal diseases. Firstly, there is an increased emphasis on expanding vaccination coverage, especially in low and middle-income countries, propelled by global health organizations and initiatives like Gavi, the Vaccine Alliance. There's also a notable shift towards the development of broader-spectrum vaccines, aiming to cover a wider range of pneumococcal serotypes prevalent in different regions. Research and development in the vaccine space are surging, with companies aiming to enhance vaccine efficacy, stability, and distribution methods. Another critical trend is the growing awareness campaigns and government-driven immunization programs, emphasizing the importance of pneumococcal vaccination across all age groups, especially in children and the elderly.
Additionally, public-private partnerships are facilitating quicker development, production, and distribution of vaccines, ensuring broader access. With the rising global focus on preventive healthcare and the challenges posed by evolving bacterial strains, the pneumococcal vaccine market is set to experience sustained growth and diversification.
Global Pneumococcal Vaccine Market Segmentation
Market Breakup by Vaccine Type
- Conjugate Vaccine
- Polysaccharide Vaccine
Market Breakup by Product Type
- Prevnar 13
- Synflorix
- neumovax23
Market Breakup by Distribution Channel
- Distribution Partner Companies
- Non-Governmental Organizations
- Government Authorities
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Pneumococcal Vaccine Market Overview
The global pneumococcal vaccine market plays a pivotal role in the broader immunization landscape, given the severity of diseases caused by the Streptococcus pneumoniae bacteria. This market has witnessed robust growth, driven by the heightened recognition of the importance of preventive measures against pneumococcal diseases, which can lead to conditions such as pneumonia, meningitis, and sepsis. The demand for both primary types of pneumococcal vaccines, namely the pneumococcal conjugate vaccine (PCV) and the pneumococcal polysaccharide vaccine (PPSV), remains substantial, catering to different age groups and health demographics.
While developed regions like North America and Europe have seen extensive vaccine coverage, concerted efforts are underway to expand immunization in low and middle-income countries. Collaborative initiatives, involving global health bodies and organizations like Gavi, have been instrumental in facilitating this expansion. With evolving bacterial serotypes, the push for broader-spectrum vaccines is gaining momentum, leading to increased research and development activities. As global health priorities continue to emphasize preventive measures and improved access to vaccines, the pneumococcal vaccine market is poised for continued growth and expansion in the coming years.
Global Pneumococcal Vaccine Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- GlaxoSmithKline, Plc.
- Sanofi
- Merck & Co.
- Panacea Biotech
- Pfizer Inc
- PnuVax Incorporated
- SK bioscience
- Walvax Biotechnology Co.
- Beijing Minhai Biotechnology Co.
- Serum Institute of India
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Pneumococcal Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Pneumococcal Disease Epidemiology Analysis - 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Pneumococcal Disease Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Pneumococcal Disease Epidemiology Forecast (2017-2032)
5.3.1 Germany Pneumococcal Disease Epidemiology Forecast (2017-2032)
5.3.2 France Pneumococcal Disease Epidemiology Forecast (2017-2032)
5.3.3 Italy Pneumococcal Disease Epidemiology Forecast (2017-2032)
5.3.4 Spain Pneumococcal Disease Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Pneumococcal Disease Epidemiology Forecast (2017-2032)
5.4 Japan Pneumococcal Disease Epidemiology Forecast (2017-2032)
6 Pneumococcal Vaccine Market Overview - 7MM
6.1 Pneumococcal Vaccine Market Historical Value (2017-2023)
6.2 Pneumococcal Vaccine Market Forecast Value (2024-2032)
7 Pneumococcal Vaccine Market Landscape - 7MM
7.1 Pneumococcal Vaccine: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Pneumococcal Vaccine Product Landscape
7.2.1 Analysis by Vaccine Type
7.2.2 Analysis by Product Type
8 Pneumococcal Vaccine Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Pneumococcal Vaccine Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter's Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Pneumococcal Vaccine Market Segmentation - 7MM
11.1 Pneumococcal Vaccine Market by Vaccine Type
11.1.1 Market Overview
11.1.2 Conjugate vaccine
11.1.3 Polysaccharide vaccine
11.2 Pneumococcal Vaccine Market by Product Type
11.2.1 Market Overview
11.2.2 Prevnar 13
11.2.3 Synflorix
11.2.4 neumovax23
11.3 Pneumococcal Vaccine Market by Distribution Channel
11.3.1 Market Overview
11.3.2 Distribution partner companies
11.3.3 Non-governmental Organizations
11.3.4 Government Authorities
11.4 Pneumococcal Vaccine Market by Region
11.4.1 Market Overview
11.4.2 United States
11.4.3 EU-4 and the United Kingdom
11.4.3.1 Germany
11.4.3.2 France
11.4.3.3 Italy
11.4.3.4 Spain
11.4.3.5 United Kingdom
11.4.4 Japan
12 United States Pneumococcal Vaccine Market
12.1 Pneumococcal Vaccine Market Historical Value (2017-2023)
12.2 Pneumococcal Vaccine Market Forecast Value (2024-2032)
12.3 Pneumococcal Vaccine Market by Vaccine Type
12.4 Pneumococcal Vaccine Market by Product Type
13 EU-4 and United Kingdom Pneumococcal Vaccine Market
13.1 Pneumococcal Vaccine Market Historical Value (2017-2023)
13.2 Pneumococcal Vaccine Market Forecast Value (2024-2032)
13.3 Germany Pneumococcal Vaccine Market Overview
13.3.1 Pneumococcal Vaccine Market by Vaccine Type
13.3.2 Pneumococcal Vaccine Market by Product Type
13.4 France Pneumococcal Vaccine Market Overview
13.4.1 Pneumococcal Vaccine Market by Vaccine Type
13.4.2 Pneumococcal Vaccine Market by Product Type
13.5 Italy Pneumococcal Vaccine Market Overview
13.5.1 Pneumococcal Vaccine Market by Vaccine Type
13.5.2 Pneumococcal Vaccine Market by Product Type
13.6 Spain Pneumococcal Vaccine Market Overview
13.6.1 Pneumococcal Vaccine Market by Vaccine Type
13.6.2 Pneumococcal Vaccine Market by Product Type
13.7 United Kingdom Pneumococcal Vaccine Market Overview
13.7.1 Pneumococcal Vaccine Market by Vaccine Type
13.7.2 Pneumococcal Vaccine Market by Product Type
14 Japan Pneumococcal Vaccine Market
14.1 Pneumococcal Vaccine Market Historical Value (2017-2023)
14.2 Pneumococcal Vaccine Market Forecast Value (2024-2032)
14.3 Pneumococcal Vaccine Market by Vaccine Type
14.4 Pneumococcal Vaccine Market by Product Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 GlaxoSmithKline, Plc.
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Sanofi
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Merck & Co.
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Panacea Biotech
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Pfizer Inc
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 PnuVax Incorporated
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 SK bioscience
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Walvax Biotechnology Co.
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Beijing Minhai Biotechnology Co.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Serum Institute of India
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
22 Pneumococcal Vaccine Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security